The First Clinical Trial of Beta-Calcium Pyrophosphate as a Novel Bone Graft Extender in Instrumented Posterolateral Lumbar Fusion.
10.4055/cios.2011.3.3.238
- Author:
Jae Hyup LEE
1
;
Bong Soon CHANG
;
Ul Oh JEUNG
;
Kun Woo PARK
;
Min Seok KIM
;
Choon Ki LEE
Author Information
1. Department of Orthopedic Surgery, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial ; Research Support, Non-U.S. Gov't ; Randomized Controlled Trial
- Keywords:
Beta-calcium pyrophosphate;
Bone graft extender;
Fusion rate;
Lumbar posterolateral fusion;
Prospective consecutive study
- MeSH:
Adult;
Aged;
*Bone Substitutes;
*Bone Transplantation;
Calcium Pyrophosphate/*administration & dosage;
Female;
Humans;
Ilium;
Imaging, Three-Dimensional;
Lumbar Vertebrae/radiography/*surgery;
Male;
Middle Aged;
Spinal Fusion/*methods;
Tomography, X-Ray Computed
- From:Clinics in Orthopedic Surgery
2011;3(3):238-244
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Porous beta-calcium pyrophosphate (beta-CPP) was developed to improve the fusion success of posterolateral lumbar fusion (PLF). The possibility of accomplishing PLF using a mixture of porous beta-CPP and iliac bone was studied. This paper reports the radiologic results of PLF using the beta-CPP plus autograft for lumbar degenerative disease as a bone graft extender. METHODS: A prospective, case-matched, radiographic study evaluating the results of short segment lumbar fusion using a beta-CPP plus autograft was performed to compare the efficacy of beta-CPP plus autograft with that of an autograft alone for short segment lumbar fusion. Thirty one consecutive patients (46 levels) underwent posterolateral fusion with pedicle screw fixation and additional posterior lumbar interbody fusion. In all patients, 3 mL of beta-CPP plus 3 mL of autogenous bone graft was placed randomly in one side of a posterolateral gutter, and 6 mL of autogenous iliac bone graft was placed on the other. The fusion rates, volumes of fusion masses, and bone absorption percentage were evaluated postoperatively using simple radiographs and 3 dimensional computed tomography (3D-CT) scans. RESULTS: The control sides treated with an autograft showed significantly better Lenke scores than the study sides treated with beta-CPP at 3 and 6 months postoperatively, but there was no difference between the two sides at 12 months. The fusion rates (confirmed by 3D-CT) were 87.0% in the beta-CPP group and 89.1% in the autograft group, which were not significantly different. The fusion mass volumes and bone absorption percentage at 12 months postoperatively were 2.49 mL (58.4%) and 1.89 mL (69.5%) for the beta-CPP and autograft groups, respectively, and mean fusion mass volume was significantly higher in the beta-CPP group. CONCLUSIONS: beta-CPP combined with an autograft is as effective as autologous bone for grafting during instrumented posterolateral spinal fusion. These findings suggest that beta-CPP bone chips can be used as a novel bone graft extender for short-segment posterolateral spinal fusion.
